Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Conditions

Recurrence 1Neoplasms 1

Interventions

Crizotinib 2Bone Marrow Transplantation 23-Iodobenzylguanidine 2vorasidenib 1tucatinib 1tovorafenib 1tazemetostat 1taletrectinib 1olaparib 1nirogacestat 1glucarpidase 1enzalutamide 1denileukin diftitox 1copanlisib 1balstilimab 1atezolizumab 1adagrasib 1Proton Pump Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1LY3023414 1Hydrocortisone 1Carboxypeptidases 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Neoplasms × denileukin diftitox × Clear all
NCT01432483 2015-01-26

Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

Eisai Inc.

No longer available

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡